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Abstract: Recent advances have indicated that osteocalcin, and in particular its undercarboxylated
form (ucOC), is not only a nutritional biomarker reflective of vitamin K status and an indicator
of bone health but also an active hormone that mediates glucose metabolism in experimental
studies. This work has been supported by the putative identification of G protein-coupled receptor,
class C, group 6, member A (GPRC6A) as a cell surface receptor for ucOC. Of note, ucOC has been
associated with diabetes and with cardiovascular risk in epidemiological studies, consistent with
a pathophysiological role for ucOC in vivo. Limitations of existing knowledge include uncertainty
regarding the underlying mechanisms by which ucOC interacts with GPRC6A to modulate metabolic
and cardiovascular outcomes, technical issues with commonly used assays for ucOC in serum,
and a paucity of clinical trials to prove causation and illuminate the scope for novel health
interventions. A key emerging area of research is the role of ucOC in relation to expression of
GPRC6A in muscle, and whether exercise interventions may modulate metabolic outcomes favorably
in part via ucOC. Further research is warranted to clarify potential direct and indirect roles for ucOC
in human health and cardiometabolic diseases.
Keywords: osteocalcin; undercarboxylated osteocalcin; GPRC6A; insulin resistance; diabetes;
cardiovascular disease; bone; muscle
1. Introduction—Osteocalcin and Undercarboxylated Osteocalcin
The objectives of the present review are to highlight the role of osteocalcin, in particular its
undercarboxylated form, as a hormone that regulates glucose homeostasis and cardiometabolic risk,
by summarizing the available experimental and human evidence. Additionally, the emerging evidence
implicating undercarboxylated osteocalcin in muscle function and glucose uptake, and its therapeutic
potential for addressing cardiometabolic diseases are discussed.
Osteocalcin is a 49 amino acid polypeptide protein with a 5.7 KDa molecular weight. It is also
known as gamma-carboxyglutamic acid-containing protein or bone gla protein [1]. Osteocalcin is the
most abundant non-collagenous protein within the bone matrix, primarily produced by osteoblasts
during the late stage of their differentiation [2]. However, the exact role of osteocalcin in the control of
bone matrix formation, mineralization or maintenance is not fully understood [3]. In osteoblasts, after
protein translation at the endoplasmic reticulum, osteocalcin undergoes carboxylation at the 17, 21 and
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24 glutamic acid (Glu) residues by γ-glutamyl carboxylase. This process is facilitated by vitamin K.
This post-translational modification changes the conformation of the osteocalcin protein, resulting in
an increased affinity for the calcium ions exposed at the surface of the hydroxyapatite crystal in the
bone matrix [2,4]. However, not all osteocalcin in bone is fully carboxylated, with a small amount of
osteocalcin still containing one (mostly Glu17) or more empty Glu residue(s), collectively denoted as
undercarboxylated osteocalcin (ucOC) [5].
Osteocalcin in the circulation is a marker of bone turnover [4]. Of the total amount of osteocalcin
that is released into the circulation, a substantial proportion (40–60%) is ucOC, the amount of which
is sensitive to vitamin K intake [3,5–7]. As such, a higher percentage of ucOC is a marker for
vitamin K status, generally indicative of lower vitamin K availability [8–10]. Furthermore, a higher
percentage of ucOC has been associated with increased risk of bone fracture in older adults, particularly
women [11–13]. Therefore, the detection of circulating ucOC has long been recognized as having
clinical predictive value as a nutritional biomarker and indicator of fracture risk. In addition, recent
studies have illuminated a role for ucOC to regulate insulin secretion by beta cells and adiponectin by
fat cells [14,15].
2. Osteocalcin, Glucose Homeostasis and GPRC6A—Experimental Studies
2.1. Osteocalcin, Undercarboxylated Osteocalcin and Glucose Metabolism
It has been hypothesized that bone may be involved in energy regulation to ensure the energy
supply needed during bone remodeling, which encompasses the cellular machinery responsible for
maintaining the integrity of bone composition, structure and strength [14]. In 2007, the Karsenty
group were the first to demonstrate that circulating ucOC regulates whole-body energy metabolism
via mechanisms that involved increasing insulin secretion from pancreatic beta cells, as well
as enhancing insulin sensitivity in peripheral tissues [15]. In this research, enteroccocal surface
protein (Esp)-knockout mice (Esp−/−) lacking an osteoblast-expressed receptor-like protein tyrosine
phosphatase (OST-PTP) exhibited increased β-cell proliferation, increased insulin and reduced glucose
concentrations, and were protected from developing a diabetic phenotype [15]. Of note, this phenotype
was completely reversed by the deletion of a single allele of the osteocalcin gene (Ocn), resulting in mice,
which had a higher proportion of circulating osteocalcin in the undercarboxylated form and implicating
osteocalcin as a regulator of glucose homeostasis. Ocn-knockout mice did not display a distinct bone
phenotype, but later in life became glucose intolerant and obese with reduced pancreatic β-cell
expression and insulin content [15]. Furthermore, administration of exogenous ucOC to wild-type
mice improved insulin production and sensitivity supporting ucOC as the metabolically active form of
osteocalcin [16,17]. Since then, independent research groups have confirmed that ucOC is involved in
energy metabolism, however, the level of involvement is still not clear [18]. One group has reported
that knockout of the osteocalcin gene in rats using the CRIPR/Cas9 method did not affect body weight
or fasting glucose concentrations [19]. Recent experimental studies have implicated ucOC in muscle
growth [20], male fertility [21], brain development and cognition [22], and anti-tumour immunity [23].
2.2. GPRC6A as a Putative Receptor for Undercarboxylated Osteocalcin
In keeping with an endocrine role for ucOC, G protein-coupled receptor, class C, group 6, member
A (GPRC6A) has been identified by several groups as a putative receptor of ucOC [24–26]. GPRC6A
belongs to the C family of G protein-coupled receptors and is widely expressed in cells of a number of
human tissues such as skeletal muscle, brain, lung, liver, heart, kidney, pancreas, placenta, spleen, ovary,
testis, prostate, leukocytes, and monocytes [25]. Expression of GPRC6A has also been documented
in mouse muscle [20,27]. It has been shown that either global or tissue-specific knockout of GPRC6A
leads to the loss of endocrine functions of ucOC in mice [21,24]. Furthermore, several studies have
reported that the deficiency of GPRC6A in mouse tissues or cultured cells results in the absence of
ucOC-induced activation of downstream signaling pathways [28–31]. By using computational docking
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models, Min Pi et al., [32] predicted that the C-terminal hexapeptide of ucOC docks to the extracellular
side of the transmembrane domain of GPRC6A. Consistently, they also showed that the mutation
of a computationally-identified binding site of GPRC6A decreased the activation of this receptor by
ucOC C-terminal hexapeptide [32]. It is worth noting, however, that to date there is still no evidence of
direct binding between ucOC and GPRC6A, thus it remains possible that GPRC6A only functions as
a crucial upstream regulator, rather than the direct receptor, in the ucOC-triggered signaling cascade.
Moreover, consensus on the role of GPRC6A in ucOC signaling is lacking, as some studies have shown
that in vitro treatment of ucOC failed to activate GPRC6A that was exogenously expressed in CHO or
HEK273 cells [33,34]. Therefore, whether GPRC6A is the receptor by which ucOC exerts endocrine
functions in vivo requires further investigation.
2.3. Summary
• Undercarboxylated osteocalcin regulates insulin secretion and sensitivity in mice
• A G protein-coupled receptor GPRC6A is implicated in the actions of undercarboxylated
osteocalcin in experimental studies
3. Osteocalcin, Diabetes and Cardiovascular Risk—Clinical and Epidemiological Studies
3.1. Osteocalcin, Metabolic Syndrome and Diabetes Risk
Clinical and epidemiological studies have examined associations of circulating osteocalcin with
endpoints related to metabolic syndrome and diabetes (Table 1). Generally these were cross-sectional
analyses assessing total circulating osteocalcin which have associated lower osteocalcin concentrations
with higher risk of Type 2 diabetes [35–37], higher body mass index (BMI) and plasma glucose
concentrations [37,38], lower insulin sensitivity [39,40]. In a large epidemiological study of 2493 men
and women, lower osteocalcin concentrations were associated with higher BMI, fasting glucose
and insulin resistance [41]. In another large epidemiological study of 2765 older men, lower
osteocalcin concentrations were associated with higher waist circumference, glucose and triglyceride
concentrations, and insulin resistance [42]. In both of those studies, adults with lower osteocalcin
concentrations had a higher risk of having metabolic syndrome [41,42]. Subsequent studies have
largely confirmed these findings, reinforcing the association of lower osteoalcin concentrations with
insulin resistance and with metabolic syndrome in men and in postmenopausal women [43–52].
In keeping with these studies, a meta-analysis of observational studies confirmed that circulating
total osteocalcin concentrations were lower in adults with metabolic syndrome or Type 2 diabetes [53].
Therefore there are ample observational studies in humans which support a pathophysiological role
for osteocalcin in regulation of glucose metabolism and diabetes risk in vivo. However, there are two
major limitations of these studies: firstly, causality cannot be inferred from cross-sectional analyses
and one longitudinal analysis did not show an association of osteocalcin with incidence of Type 2
diabetes [46]. Secondly, data on circulating ucOC which is postulated to be the metabolically active
form binding to GPRC6A were not reported in those studies (Table 1).
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Table 1. Selected studies examining associations of total circulating osteocalcin (TOC) with insulin
resistance, metabolic syndrome and diabetes in men and women are summarised. X = cross-sectional
analysis, L = longitudinal analysis, I = interventional component, HOMA = homeostasis model
assessment, HOMA-B = β-cell activity, HOMA-IR = insulin resistance.
First Author, Year [ref no.] Study (Type) Results
Im J-A, 2008 [35] 339 post-menopausal women,31 with Type 2 diabetes (X)
Serum TOC was lower in women with Type 2
diabetes vs. controls (17.5 vs. 22.2 µg/L), and correlated
inversely with HbA1c (r = −0.22) and IR (r = −0.16)
Zhou M, 2009 [36]
254 men (128 newly diagnosed Type 2
diabetes) and 180 postmenopausal
women (92 with diabetes) (X)
Serum TOC was lower in adults with Type 2
diabetes vs. controls (15.1 vs. 16.8 µg/L).
Kindblom JM, 2009 [37] 857 non-diabetic and 153 diabetic men (X)
Diabetic men had lower TOC (21.7 vs. 27.8 µg/L),
TOC was inversely related to body mass index (BMI),
fat mass and fasting glucose.
Kanazawa I, 2009 [38] 179 men and 149 post-menopausalwomen with Type 2 diabetes (X)
TOC correlated negatively with fasting plasma glucose
(r = −0.24 for men, −0.19 for women) and HbA1c
(r = −0.16, −0.27). TOC correlated with total
adiponectin in women (r = 0.30).
Fernandez-Real JM, 2009 [39] 149 non-diabetic men (X),and 46 non-diabetic men and women (I)
Serum TOC correlated with insulin sensitivity (r = 0.23),
and total adiponectin (r = 0.19). TOC was increased by
dietary weight loss (16.8% of body weight) or
weight loss (8.7%) + exercise.
Pittas AG, 2009 [40] 380 men and women (X), 198 (L),5% with diabetes
Serum TOC inversely correlated with fasting glucose,
insulin and IR. Higher TOC associated with lower rise in
fasting glucose over 3 years.
Saleem U, 2010 [41] 2493 men and women (X)
Serum TOC inversely correlated with BMI, fasting glucose,
IR and leptin, positively correlated with adiponectin. TOC in
highest quartile associated with reduced odds of
metabolic syndrome.
Yeap BB, 2010 [42] 2765 older men with metabolic syndromepresent in 797 (28.8%) (X)
TOC level was inversely associated with waist
circumference, glucose, triglyceride levels and IR, and was
lower in men with metabolic syndrome (20.1 vs. 21.4 µg/L).
Men with TOC of 13.3–16.6 and <13.3 µg/L had 1.5 to 2-fold
increased risk of metabolic syndrome compared to men with
TOC ≥ 30 µg/L.
Tan A, 2011 [43] 2344 men aged 20–69 years (X)
TOC correlated with HDL and was inversely associated with
BP, glucose, triglycerides, waist circumference and BMI.
Men with TOC in the lowest quartile had a higher odds ratio
for having metabolic syndrome.
Bao Y, 2011 [44] 181 men who underwent coronaryangiography (X)
TOC was lower in men with metabolic syndrome.
In a subgroup of 60 men with normal glucose tolerance men
with multi-vessel coronary artery disease had lower TOC
compare to men without coronary artery disease.
Bae SJ, 2011 [45] 567 men and postmenopausal women (X)
TOC was lower in postmenopausal women with metabolic
syndrome (18.9 vs. 22.5 ug/L) and in men with metabolic
syndrome (14.6 vs. 16.1 ug/L) compared to those
without metabolic syndrome.
Lee SW, 2012 [46] 214 postmenopausal women (X) TOC was not associated with fasting glucose, but wasinversely associated with HOMA-IR
Movahed A, 2012 [47] 382 postmenopausal women (X) Lower TOC was associated with higher odds ratio ofhaving Type 2 diabetes
Hwang Y-C, 2012 [48]
1229 men aged 25–60 years without
diabetes at baseline, of which
90 developed Type 2 diabetes during
mean follow-up of 8.4 years (L)
Baseline TOC in tertiles was inversely associated with
HOMA-IR in cross-sectional analysis, but was not associated
with incident Type 2 diabetes in longitudinal analysis.
Oosterwerff MM, 2013 [49] 1284 persons (629 men and 655 women)aged 65–88 years (X)
TOC was inversely associated with metabolic syndrome
with odds ratio 3.7 for those with TOC in the lowest
compared to the highest quartile of values.
Yang R, 2013 [50] 1789 postmenopausal women aged41–78 years (X)
TOC was lower in women with metabolic syndrome
(18.5 vs. 21.1 ug/L) compared to those without.
Women with higher TOC had lower
odds ratio for metabolic syndrome.
Confavreux CB, 2014 [51] 798 men aged 51–85 years (X) Higher TOC was associated with lower odds ratiofor metabolic syndrome.
Kang J-H, 2016 [52] 98 persons (24 men and 74 women)mean age 53.5 years (X)
TOC was inversely associated with fasting glucose and
HOMA-IR, but not with atherosclerotic plaque in the subset
of 31 persons who had coronary CT angiography.
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3.2. Measuring Circulating Undercarboxylated Osteocalcin Concentrations
Standard immunoassays for osteocalcin (Table 1) recognise both carboxylated and
undercarboxylated forms, giving a result for total circulating osteocalcin. Currently two methods
are used to measure circulating ucOC concentrations. The hydroxyapatite (HAP) binding assay uses
HAP to bind carboxylated osteocalcin which is then removed by centrifugation, after which ucOC
is measured by immunoassay in the serum supernatant [54]. While this method should identify
the metabolically active form of osteocalcin [15], it is technically more involved than a single-step
immunoassay. Direct immunoassays use antibodies against ucOC; however, a commonly used
commercially available ucOC antibody (Takara Shuzo Co., Kyoto, Japan) overestimates large ucOC
fragments that can lead to inaccuracies in determination of ucOC or the ratio of ucOC to total
osteocalcin [54]. Furthermore, this ucOC antibody might not reliably detect ucOC when uncarboxylated
only at the Glu-17 position [55,56]. Therefore measurement of ucOC is not straightforward and
frequently used methods do not distinguish the number and position of uncarboxylated Glu residues,
and these limitations need to be considered in the interpretation of results. Compared to studies
reporting total osteocalcin concentrations (Table 1), clinical and epidemiological studies, which have
examined associations of ucOC with endpoints related to metabolic syndrome and diabetes tend to be
smaller in size, at least in part due to the added requirement for assay of ucOC (Table 2).
Table 2. Selected studies examining associations of undercarboxylated osteocalcin (ucOC) with insulin
resistance, metabolic syndrome and diabetes in men and women are summarised. X = cross-sectional
analysis, L = longitudinal analysis, I = interventional component, HOMA = homeostasis model
assessment, HOMA-B = β-cell activity, HOMA-IR = insulin resistance, TOC = total osteocalcin,
P1NP = N-terminal propeptide of type I collagen, CTX = collagen type I C-terminal cross-linked
telopeptide. * ucOC assayed using hydroxyapatite binding, # ucOC assayed using ucOC antibody.
First Author,
Year [ref no.] Study (Type) ucOC Assay Results
Hwang Y-C, 2009 [57] 199 men (X) # Higher ucOC associated with greater insulinsensitivity (HOMA-B).
Shea MK, et al., 2009 [58] 348 non-diabetic men and women(M = 142, F = 206) (X, L) *
Higher total and carboxylated OC levels (not ucOC) associated
with insulin sensitivity, association attenuated by adjustment for
adiponectin. Higher carboxylated OC level at baseline predicted
less change in IR at 3 years, lower % ucOC predicted greater
increase in IR.
Kanazawa I, 2009 [59] 50 men and women with poorlycontrolled Type 2 diabetes (L) #
After one month of improved glycemic control, TOC level
increased, ucOC was unchanged but the ratio
of ucOC/TOC decreased.
Kanazawa I, 2011 [60] 180 men and 109 postmenopausalwomen with Type 2 diabetes (X) #
ucOC was inversely correlated with fasting glucose and HbA1c in
men, but not in postmenopausal women.
Levinger I, 2011 [61] 28 men aged 52.4 years with BMI32.1 kg/m2 (X, I) #
ucOC inversely correlated with fasting glucose and HbA1c,
ucOC increased following aerobic and strength exercise.
Bullo M, 2012 [62] 79 men aged 55–80 years withcardiovascular risk factors (X, L) #
Baseline ucOC was not associated with HOMA-IR at
2 years, change in ucOC was inversely associated with change in
HOMA-IR over 2 years.
Iki M, 2012 [63] 1597 men aged ≥65 years (X) #
TOC and ucOC were correlated (correlation coefficient 0.66).
TOC and ucOC in quintiles were inversely associated with fasting
glucose, HbA1c and HOMA-IR. Inverse association of ucOC with
these outcomes remains significant after adjusting for TOC
(but not vice versa). Higher quintiles of ucOC were associated
with lower odds ratios for prevalent Type 2 diabetes (but not
TOC).
Mori K, 2012 [64] 129 adults with Type 2 diabetesmean age 54.9 years (X) #
ucOC was not associated with insulin resistance using euglycemic
hyperinsulinemic clamp in adults with Type 2 diabetes
Thrailkill KM, 2012 [65] 115 adults with Type 1 diabetes and55 controls mean age 18.8 years #
No difference in ucOC between adults with Type 1 diabetes and
controls. ucOC was inversely associated with HbA1c.
Diaz-Lopez A, 2013 [66]
153 adults with newly diagnosed
Type 2 diabetes and 306 matched
controls, mean age 66.3 years
#
Carboxylated osteocalcin (not ucOC) was inversely associated
with HOMA-IR in cases, and fasting glucose in controls. Lower
carboxylated osteocalcin or ucOC in tertiles were associated with
higher odds ratio for incident diabetes.
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Table 2. Cont.
First Author,
Year [ref no.] Study (Type) ucOC Assay Results
Gower BA, 2013 [67]
63 overweight/obese adults with
normal (N = 39) or impaired fasting
glucose (N = 24) (X)
*
TOC was associated with insulin sensitivity in the whole cohort.
ucOC was associated with indices of β cell response in the subset
with impaired fasting glucose.
Levinger I, 2014 [68] 11 men aged 58.1 years with BMI33.1 kg/m2 (I) *
Exercise increased ucOC and ucOC/TOC ratio, reduced glucose
concentrations and improved insulin sensitivity.
Saucedo R, 2015 [69]
60 women with gestational diabetes
and 60 with normal glucose
tolerance (X)
# No difference in TOC or ucOC in women with gestationaldiabetes compared to women with normal glucose tolerance.
Yeap BB, 2015 [70] 2966 men aged ≥70 years (X) *
Higher ucOC was associated with reduced diabetes risk
(odds ratio per 1 SD increase after adjusting for conventional risk
factors = 0.55). Similar results were seen for TOC, P1NP and CTX.
When all 4 markers were included in the fully adjusted model,
higher ucOC remained associated with reduced diabetes risk
(odds ratio 0.56) while TOC was no longer associated.
Bonneau J, 2017 [56]
129 overweight/obese
postmenopausal women without
diabetes mean age 57.7 years (X)
#
Ratio of carboxylated to total osteocalcin correlated inversely with
insulin sensitivity assessed using euglycemic hyperinsulinemic
clamp and positively with HOMA-IR in postmenopausal women.
Takashi Y, 2017 [71] 50 adults with Type 2 diabetes meanage 59.2 years (X) #
ucOC correlated with change in C-peptide following glucagon,
and C-peptide response to eating a meal.
Yeap BB, 2017 [72] 108 adults with Type 1 diabetesmean age 39.1 years (X) *
ucOC was not associated with fasting glucose, HbA1c or daily
insulin dose in adults with Type 1 diabetes.
3.3. Studies Associating Undercarboxylated Osteocalcin with Diabetes Risk in Men
A number of studies have reported ucOC results in relation to metabolic outcomes (Table 2).
Several cross-sectional studies in men have documented associations of ucOC with glucose metabolism
in vivo [57,63,70]. Two studies are of particular interest. A large epidemiological study of 1597 men
aged ≥65 years found that ucOC was inversely associated with measures of glycemia and insulin
resistance, remaining so after adjustment for total osteocalcin [63]. Another large epidemiological
study, the Western Australian Health In Men Study (HIMS), analysed 2966 men aged ≥70 years
in whom ucOC was assayed using a HAP-binding assay and also examined total osteocalcin and
two non-osteocalcin markers of bone turnover, N-terminal propeptide of type I collagen (P1NP)
and collagen type I C-terminal cross-linked telopeptide (CTX) [70]. That HIMS analysis found that
all four bone turnover markers were inversely associated with diabetes risk; however, when all
four were included in a multivariate model that included adjustment for conventional risk factors,
ucOC remained robustly associated with diabetes risk while total osteocalcin and P1NP were no longer
associated and the association of CTX was attenuated [70]. These epidemiological findings support the
concept of ucOC being a predictor of diabetes risk in older men, distinct from total osteocalcin or other
bone turnover markers. In a longitudinal study, an increase in ucOC was associated with a reduction
in insulin resistance in men over an interval of two years [62].
3.4. Other Studies of Undercarboxyated Osteocalcin and Glucose Metabolism
In a study of 348 non-diabetic men and women, ucOC measured using a HAP-binding assay
was not associated with insulin sensitivity at baseline; however, a lower % of ucOC predicted greater
increase in insulin resistance at follow-up [58]. In a study of 129 overweight postmenopausal women
without diabetes, a greater ratio of carboxylated to total osteocalcin correlated inversely with insulin
sensitivity, supporting in an indirect manner a role for ucOC in regulation of glucose metabolism in
women [56]. One study in 63 overweight or obese adults found an association of ucOC with β cell
responses only in the subset of adults with impaired fasting glucose but not in those with normal
glucose tolerance [67]. In studies of overweight men, ucOC was inversely correlated with fasting
glucose and HbA1c, and both ucOC and the ratio of ucOC to total osteocalcin increased following
exercise [61,68].
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3.5. Studies of Undercarboxylated Osteocalcin in Adults with Diabetes
Several studies of ucOC have been reported in adults with Type 2 diabetes (Table 2). A case-control
analysis of 153 adults with newly diagnosed Type 2 diabetes and 306 controls reported an association
of both carboxylated osteocalcin and ucOC with risk of diabetes [66]. While some studies have not
shown strong associations of ucOC with indices of glycemia [59,64] other studies have supported a role
for ucOC as a marker for better indices of glycemia in adults with Type 2 diabetes [60,71]. Of note,
while these studies relate ucOC to insulin sensitivity and Type 2 diabetes, ucOC does not appear to be
associated with indices of glycemia in the setting of gestational diabetes [69] and the role of ucOC in
Type 1 diabetes remains uncertain [65,72]. Therefore, there is observational data supporting a role for
ucOC to modulate risk of Type 2 diabetes, particularly in older men. The role of ucOC to modulate
glucose metabolism once Type 2 diabetes is already present is less clear.
3.6. Osteocalcin and Cardiovascular Risk
Diabetes has long been recognised as a cardiovascular risk factor, whose presence is predictive of
cardiovascular events and mortality [73–75]. Therefore, given the experimental and epidemiological
evidence linking osteocalcin and ucOC with diabetes risk, the next question is whether or not
osteocalcin and in particular ucOC by modulating cardiometabolic health influence the incidence of
cardiovascular events and mortality. Several epidemiological studies have examined associations of
osteocalcin with outcomes related to cardiovascular events and mortality (Table 3). In a cross-sectional
study of 461 adults undergoing coronary angiography, those with proven coronary artery disease
had lower total circulating osteocalcin as a group [76]. A longitudinal study of 781 men found no
association of total osteocalcin with mortality [77]. In a longitudinal analysis from HIMS of 3542 men
aged ≥70 years, there was a U-shaped association of total osteocalcin with all cause and cardiovascular
mortality [78]. Subsequent studies have reported associations of higher baseline total osteocalcin
with lower all-cause mortality, and lower baseline total osteocalcin with all-cause and cardiovascular
mortality in men [79,80], and a U-shaped association of total osteocalcin with non-cardiovascular
but not all-cause or cardiovascular mortality in women [81]. Therefore, on balance, lower total
osteocalcin appears to be a predictor of all-cause and cardiovascular mortality in men, while additional
research is needed to clarify the prognostic implications of high total osteocalcin concentrations in
men. The association of total osteocalcin with mortality in women is less clear. However, these studies
are limited by the lack of ucOC data.
Table 3. Selected studies examining associations of total osteocalcin (TOC) and undercarboxylated
osteocalcin (ucOC) with outcomes related to cardiovascular disease and mortality. X = cross-sectional
study, L = longitudinal study, CHD = coronary heart disease. * ucOC assayed using hydroxyapatite
binding, # ucOC assayed using ucOC antibody, N/A = no ucOC results reported.
First Author,
Year [ref no.] Study (Type) ucOC Assay Results
Szulc P, 2009 [77] 781 men aged ≥50 years (L) N/A TOC was not associated with mortality, while higher boneresorption markers were associated.
Yeap BB, 2010 [78] 3542 men aged 70–89 years followed for5.2 years (L) N/A
U-shaped association of TOC with all-cause and
cardiovascular mortality.
Zhang Y, 2010 [76]
461 adults (243 with CHD and
218 without) undergoing coronary
angiography (X)
N/A TOC was lower in group with CHD.
Confavreux CB, 2013 [79] 774 men aged 51–85 years followed for10 years (L) N/A
Higher baseline TOC was associated with less progression
of abdominal aortic calcification and
lower all-cause mortality.
Lerchbaum E, 2013 [80] 2271 men referred for coronaryangiography (L) N/A
Association of TOC in lowest quintile with all-cause and
cardiovascular mortality.
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Table 3. Cont.
First Author,
Year [ref no.] Study (Type) ucOC Assay Results
Lerchbaum E, 2014 [81] 986 women aged 58–72 years (L) N/A
U-shaped association of TOC with non-cardiovascular
mortality, TOC was not associated with all-cause or
cardiovascular mortality.
Choi S-H, 2015 [82] 162 adults (114 men and 48 women) (X) #
Higher ucOC and ratio of ucOC/TOC found in men with
coronary artery calcification
(no differences found in women).
Yeap BB, 2015 [83] 3384 men aged 70–89 years followed for7 years (L) *
Higher ratio of ucOC/TOC was associated with lower
incidence of myocardial infarction, but was not
associated with stroke.
3.7. Circulating Undercarboxylated Osteocalcin and Cardiovascular Risk
A cross-sectional analysis involving 114 men reported an association of higher ucOC and
an increased ucOC/total osteocalcin ratio with coronary artery calcification [82]. The significance of
this finding, however, is uncertain as the sample size was relatively small, the cross-sectional nature
of the analysis precludes attribution of causation and no association was seen in women. Of note,
a more recent longitudinal analysis from HIMS of 3384 men aged 70–89 years followed for seven years
demonstrated an association of higher ucOC/total osteocalcin ratio with lower incidence of myocardial
infarction after adjusting for conventional cardiovascular risk factors [83]. In HIMS, the ratio of ucOC
to total osteocalcin was not predictive of stroke, suggesting a differential influence on distinct vascular
territories. Those findings support the concept that the proportion of circulating ucOC functions as
a biomarker for incidence of myocardial infarction. The possible underlying mechanisms and whether
interventions that result in a greater proportion of circulating ucOC would reduce cardiovascular risk
remain to be elucidated.
3.8. Matrix Gla Protein and Cardiovascular Risk
Of note, matrix γ-carboxyglutamic acid (Gla) protein (MGP) is a peptide associated with
the organic phase of bone and cartilage, which shares substantial homology with osteocalcin [4].
MGP is expressed in chondrocytes and vascular smooth muscle, and acts as an inhibitor of vascular
calcification [84,85]. MGP undergoes γ-carboxylated at Glu residues under the influence of vitamin K
and uncarboxylated forms of MGP in the circulation have been associated with arterial stiffness in
adults, and with peripheral arterial calcification and incidence of cardiovascular events in patients
with Type 2 diabetes [86–88]. However, it is unclear whether or not there is an analogous role for ucOC
to modulate vascular calcification and thereby risk of cardiovascular events.
3.9. Summary
• Epidemiological studies associate lower circulating total osteocalcin concentrations with insulin
resistance and risk of Type 2 diabetes
• Methods for assay of circulating undercarboxylated osteocalcin need to be optimised
• Epidemiological studies associate lower circulating concentrations of undercarboxylated
osteocalcin, or a lower ratio of undercarboxylated to total osteocalcin, with risk of Type 2 diabetes
and incidence of myocardial infarction
4. Osteocalcin, Exercise and Muscle Function—Experimental Studies
4.1. Putative Interaction of Bone, Muscle and Metabolism
The initial discovery of a metabolic role for ucOC focused attention on insulin sensitivity and
diabetes risk [15–17]. Whilst these initial studies did not focus primarily on muscle, it should be noted
that skeletal muscle plays a major role in glucose uptake and utilization [89,90]. It is a major site for
nutrient storage and energy expenditure [91,92]. In keeping with the importance of skeletal muscle in
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glucose metabolism, increasing interest has focused on the link between bone, muscle and metabolism,
via a potential role of ucOC acting in muscle [93].
4.2. The Role of Undercarbxoylated Osteocalcin in Skeletal Muscle: Evidence from Mouse Models
Evidence thus far has indicated that ucOC may participate in the endocrine modulation of
skeletal muscle functions, via the GPRC6A receptor and its downstream signaling pathways in muscle
cells [28]. In vivo studies in mice first pointed to ucOC effects in skeletal muscle insulin sensitivity
and signalling. These studies reported an association between higher serum ucOC levels due to loss
of Esp, activating transcription factor 4 (Atf4) or the class O of forkhead box transcription factor 1 (Foxo1)
expression in osteoblasts with enhanced expression of insulin target genes in skeletal muscle [94,95].
A further study showed higher insulin-stimulated muscle glucose uptake in Esp−/− mice compared to
wide type (WT) littermates. In muscle from mice subject to a high fat diet (HFD), administration of
ucOC reduced the deleterious effect of the HFD diet on gene expression and endoplasmic reticulum
stress, fat accumulation, and autophagy [96,97]. It should be noted, however, that ucOC was also able
to enhance the secretion of insulin from the pancreas [15,16], adiponectin from adipose tissue [16],
and glucagon-like peptide-1 (GLP-1) from the intestines [98,99]. Thus, the insulin-sensitising effects
of ucOC on muscle indicated by in vivo studies may be affected by indirect factors rather than
representing a purely direct.
4.3. The Role of Undercarboxylated Osteocalcin in Skeletal Muscle: Cell and Tissue-Based Studies
Other studies have been able to elucidate some of the direct effects of ucOC on muscle cells
by using in vitro and isolated (exercised) mouse muscle models. In C2C12 myotubes, a subclone
model or rapidly differentiating mouse myotubes, ucOC exposure at physiological concentrations
dose-dependently augmented insulin-stimulated glucose uptake [27,100]. Ex vivo, a 2.5-h ucOC
treatment (30 ng/mL) enhanced muscle glucose uptake in insulin-stimulated mouse soleus muscles,
but not in insulin-stimulated extensor digitorum longus (EDL) muscles [101]. It should be noted
that soleus and EDL muscles are made of distinct fiber-type compositions. While soleus primarily
consists of slow twitch type I and EDL of fast twitch type II fibers, respectively, this result indicates
that ucOC possibly favors muscle insulin sensitivity in a fiber type-specific manner [101]. Importantly,
ucOC also triggers non-insulin-stimulated glucose uptake [102]. Therefore, further investigations into
the mechanisms by which ucOC exert direct effects on muscle insulin sensitivity are warranted.
4.4. Exercise and Insulin Sensitivity: A Role for Undercarboxylated Osteocalcin?
The benefits of exercise on muscle energy metabolism and insulin sensitivity have been well
documented [103,104]. Even a single session of exercise improves insulin sensitivity for up to 48 h
following exercise [105,106]. An important and often overlooked benefit of exercise is that acute
exercise enhances glucose uptake in skeletal muscle in a pathway independent of insulin, meaning
people with insulin resistance and Type 2 diabetes may have normal glucose uptake in skeletal muscle
during and for a period following exercise [106–108]. The exact mechanism by which this interesting
phenomenon occurs remains unclear. Some reports have suggested that this post-exercise effect on
glucose uptake may be attributed to the alteration of humoral factors, one of which may indeed be
ucOC [61,68,106,109].
4.5. Exercise as a Stimulus for Increased Circulating Undercarboxylated Osteocalcin
Due to the specialized functions of bone cells, namely osteoblasts, osteoclasts and osteocytes,
bone is a dynamic tissue that responds to mechanical loading and unloading by modifying its mass
and strength via cellular driven remodeling [110]. It is thus possible that exercise, which stresses
the bone via increased mechanical loading, would have an effect on markers of bone remodeling,
including osteocalcin and ucOC [111,112]. Reports of the effect of exercise on total osteocalcin are
contentious, with some researchers describing increases in total osteocalcin concentrations with
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acute exercise [113,114], while others reported lower [115], or unchanged [116,117] total osteocalcin
concentrations shortly after exercise. The existence of these contradictory data may be due to
different exercise modes or intensities, or different time points of blood sampling during/following
exercise [111,118]. However, total osteocalcin is not the same as uOC and overall, studies seem
to agree that acute exercise associates with higher circulating ucOC concentrations. In humans,
ucOC concentrations were reported to be increased by 6–14% immediately after a single session of
high intensity aerobic exercise [61,68]. In mice, a much higher increase, up to 2.5-fold, was observed
during and shortly after a single bout of aerobic treadmill running [28].
4.6. Exercise, Undercarboxylated Osteocalcin and Insulin Sensitivity
Increases in serum ucOC concentrations following exercise may be clinically important.
As exercise improves insulin sensitivity and glycaemic control, it is likely that the increase in ucOC
may contribute to the insulin-sensitizing effect of exercise. Indeed, it was reported that a single
session of high-intensity exercise (95.1% ± 1.9% of HRpeak) by obese men increased circulating ucOC,
which correlated with enhanced insulin sensitivity following exercise [61,68]. Furthermore, analyses
from muscle biopsies revealed ucOC levels were also associated with higher insulin signaling activity
in the vastus lateralis muscle following exercise [68]. In an ex vivo mouse study where isolated
muscles were loaded into specialized contraction baths, ucOC treatment was reported to enhance
insulin-stimulated glucose uptake in EDL muscles post-ex vivo contraction, indicating a direct role for
ucOC in muscle insulin-sensitizing effect following contraction-stimulated exercise [27]. These studies
suggest a potential role for exercise as a stimulus to increase circulating ucOC, which may then, in turn,
modulate some of the beneficial effects of exercise. It should be noted that the exercise-induced ucOC
increase was usually transient [61,68], thus whether and how this short-term ucOC enhancement
contributes to muscle insulin sensitivity hours after exercise requires further exploration.
4.7. Undercarboxylated Osteocalcin and Muscle Strength
Mice lacking osteocalcin were reported to have lower muscle mass and volume compared to
their wild-type counterparts of a similar age [28]. Moreover, administration of ucOC increased
muscle mass in older mice [20]. Decreased ucOC levels were associated with reduced muscle mass
and strength, in both EDL and soleus muscles, in rats with disuse atrophy induced by hind limb
immobilization [119]. In cultured C2C12 myoblasts treatment with ucOC increased proliferation
and differentiation, effects that were mediated, at least in part, via GPRC6A [29]. Despite these
animal and cellular data suggesting an intrinsic role for ucOC in muscle function, human data are
limited. In a cross-sectional study of women aged ≥70 years in which ucOC was assayed using
a HAP-binding assay, a positive correlation was found between % ucOC and quadriceps muscle
strength [120]. In an interventional study of 62 patients with hypoparathyroidism, treatment with
recombinant parathyroid hormone (rPTH) resulted in an increase in % ucOC which was not associated
with energy metabolism [121], but was positively associated with the change of maximum force
generated in elbow extension [122]. However, in that study, the increase in ucOC was not associated
with other tests of muscle and physical performance [122]. Therefore, while there is some data to
support a role for ucOC in the regulation of muscle strength and function, in addition to its role in
muscle glucose uptake and metabolism, interventional studies are needed to determine if there is
a causative effect and whether there is scope for novel therapeutic approaches to enhance both glucose
metabolism and muscle function.
4.8. Molecular Mechanisms Underlying Undercarboxylated Osteocalcin’s Role in Insulin Resistance
The mechanisms underlying the action of ucOC in target tissues to improve insulin secretion
and sensitivity are not the major focus of the current review and as such are not described in
detail. However, substantial emerging evidence suggests that relevant molecular mechanisms include
activation of the ERK MAPK pathway in β cells [31,32] resulting in increased cell proliferation and
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insulin secretion, as well as increased insulin sensitivity in peripheral tissues via the activation of
the PI3K/Akt pathway [20,96], the cAMP/CREB pathway [20], the AS160 protein [27,101], and the
downregulation of the ER stress pathway [96,97].
4.9. Osteocalcin and Ageing: Relevance to Muscle Mass and Glucose Homeostasis
In cross-sectional studies of men and women, circulating osteocalcin is highest in early adulthood,
lower in mid-life, and higher again in older age [123–125]. How the proportion of ucOC compared
with total osteocalcin changes during ageing is less clear. In mice, there is a substantive decrease
in total circulating osteocalcin and ucOC concentrations between the ages of 2 and 9 months,
and muscle-specific deletion of Gprc6a reduced exercise capacity in young mice [28]. Interestingly,
administration of exogenous osteocalcin restored the exercise capacity of 12 and 15-month old mice to
levels comparable with 3-month old mice [28]. The human correlate is the emergence of sarcopenia and
frailty in older age, linked with an increasing incidence and prevalence of diabetes [126]. In a study
of men aged 79–97 years, those with diabetes had poorer physical performance demonstrating the
inter-relationship between ageing, deterioration of physical function and diabetes [127]. Whether
ucOC might ameliorate age-related changes in muscle and other tissues to restore physical function
and improve glucose homeostasis in humans remains to be seen.
4.10. Summary
• Undercarboxylated osteocalcin enhances muscle glucose uptake in mice and cells
• Undercarboxylated osteocalcin increases muscle mass in older mice and increases proliferation of
muscle cells
• Exercise increases circulating undercarboxylated osteocalcin and insulin sensitivity in vivo
5. Discussion and Conclusions
Our understanding of the interaction between bone and energy metabolism has been improved by
the identification of an endocrine role for ucOC in the modulation of insulin secretion and sensitivity,
and therefore risk of Type 2 diabetes. While the initial discoveries were made in experimental
mouse and cellular (in vitro) models, these were rapidly translated via observational clinical and
epidemiological studies that supported the relevance of osteocalcin, and particularly ucOC, to glucose
metabolism and diabetes risk in vivo. These studies have extended our understanding of ucOC, or the
ratio of ucOC to total osteocalcin, as predictors not only of indices of insulin resistance and risk of
Type 2 diabetes, but also of cardiovascular risk and incidence of myocardial infarction. Furthermore,
the role of ucOC in muscle function and the effects of exercise to increase circulating ucOC in vivo
illuminate new mechanisms by which exercise, bone and muscle are able to interact to regulate energy
metabolism. While GPRC6A has been postulated as the putative receptor for ucOC, including in
muscle, much more work is needed to clarify whether this is the primary route by which ucOC exerts
its actions in different tissues.
At this stage, interventional studies that prove a causal role for ucOC in the reduction of diabetes
and cardiovascular risk in humans are lacking. Anti-resorptive therapies for osteoporosis generally
reduce bone turnover markers and randomised controlled trials of these agents have not reported
differences in the incidence of diabetes in treatment vs control arms [128]. However, those trials were
never designed with incidence of diabetes as an outcome. By contrast, a retrospective analysis of
a large cohort of primary care patients prescribed anti-resorptive therapy with bisphosphonates and
practice-matched unexposed persons associated exposure to bisphosphonates with reduced risk of
Type 2 diabetes [129]. Neither of these studies reported ucOC results [128,129].
In studies involving men and women, dietary intake of vitamin K1 (phylloquinone) was associated
with insulin sensitivity [130], while dietary intakes of either vitamin K1 or K2 (menaqionones)
were associated with lower risk of Type 2 diabetes [131,132]. In another study, vitamin K2 intake
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was associated with lower occurrence of metabolic syndrome [133]. However, a higher intake of
vitamin K might reflect better nutritional quality of the diet and greater engagement in healthy
lifestyle behaviors overall, for example, consumption of leafy green vegetables which is the main
source of vitamin K1 [134]. Clinical trials of vitamin K supplementation have yielded mixed results.
In a four-week trial in premenopausal women at risk of diabetes, vitamin K1 supplementation resulted
in lower 2-h glucose concentrations and improved insulin sensitivity [135]. By contrast, a 12-month
study of vitamin K1 supplementation in postmenopausal women showed no change in indices of
glucose homeostasis [136]. A large randomized placebo-controlled trial in 355 older men and women of
36 months supplementation with vitamin K1 found less progression of insulin resistance in men, but not
in women [137]. A four-week study of vitamin K2 supplementation in healthy young men reported
increased insulin sensitivity [138]. However, studies of vitamin K2 supplementation in young men and
women, and in postmenopausal women, have found no effect on adiponectin [139,140]. A systematic
review of eight trials involving 1077 participants reported no effect of vitamin K supplementation
on insulin sensitivity, concluding that further well-designed randomized controlled trials with large
sample sizes are needed [141]. Vitamin K supplementation consistently reduced ucOC, increasing
the proportion of carboxylated osteocalcin [135,136,138–140]. Thus, the overall effect of vitamin K
supplementation on indices of glucose metabolism remains to be fully clarified, reflecting the broader
actions of vitamin K1 and K2 on pathways distinct from osteocalcin [141–144].
Dedicated interventional studies are essential to determine whether increasing circulating ucOC
or the ratio of ucOC relative to total osteocalcin would improve insulin sensitivity and thus reduce
the risk of Type 2 diabetes in humans. Administering recombinant ucOC has been informative in
mice [16,17], but this approach is logistically more challenging in humans and as yet there have been
no clinical trials of ucOC to determine its effects on diabetes and cardiovascular risk. Increasing
circulating ucOC by exercise offers an alternative interventional approach, although care would be
required in the interpretation of such studies when distinguishing the effects of exercise versus the
effects of ucOC in the pancreas, fat and muscle tissues. Thus, the endocrine role of ucOC, linking as it
may muscle, bone and metabolism to influence diabetes and cardiovascular risk, remains a key arena
for future research to improve human health.
In terms of future perspectives and research directions, additional mechanistic studies to clarify
the mechanisms by which ucOC exerts its actions in various tissues, including β-cells and muscle
would be highly valuable. Further work is needed to ascertain whether GPRC6A is a major receptor
for ucOC in these and other tissues, bearing in mind that another G-protein coupled receptor Gpr158
has been found to mediate the effect of osteocalcin on cognition in mice [145]. Epidemiological
studies utilizing robust assays for circulating ucOC will continue to provide important information
regarding the associations of ucOC in humans. The interaction of ucOC, muscle function and glucose
homeostasis is a key area further research, with exercise interventions representing a possible pathway
to manipulate ucOC with the ultimate goal of improving cardiometabolic health.
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